Echo IQ (ASX:EIQ) has announced the appointment of Cassling Diagnostic Imaging Incorporated as an exclusive sales agent for EchoSolv in the midwest region of the U.S.

The company reports this appointment builds on Echo IQ’s sales and marketing strategy as it continues to deliver on the commercialisation of its innovative EchoSolv product which is scheduled to begin in a private cardiology practice in Australia.

EchoSolv is the company’s proprietary artificial-intelligence (AI) decision-support software system that addresses the issue of under-diagnosis of structural heart disease.

“The appointment … is another important step in the commercial development of Echo IQ and is highly significant given their impressive reputation in the market”

Commenting on the appointment, Echo IQ Executive Chair, Andrew Grover said: “We are pleased to announce 2 important steps in our journey to full commercialisation.

The appointment of Cassling Diagnostic Imaging Incorporated as an agent in the USA is another important step in the commercial development of Echo IQ and is highly significant given their impressive reputation in the market.

Cassling’s decision to add EchoSolv to their portfolio is a testament to their confidence in its potential and we are pleased to see our solution sit alongside their stellar offering of complementary products and services.”

Cassling Vice President of Growth and Innovation, Elizabeth Grieger added: “Aortic stenosis is often highly treatable, but accurate disease identification is critical. This innovative technology can be easily integrated into clinical practice and used both as an audit tool and to support rea-l-time diagnosis.

We believe our hospital customers, as well as ASCs, speciality care, and outpatient centres will be eager to embrace EchoSolv as a means to improve access and outcomes, and ultimately, strengthen community healthcare.”

The agreement enables Cassling to present EchoSolv solutions to hospitals, ambulatory surgery centres and specialty care and outpatient centres in midwest states in the U.S, including Texas, Arkansas, Iowa, Missouri, Kansas, and others.

Echo IQ is using a multi-faceted distribution approach for the commercialisation of EchoSolv, whilst targeting smaller cardiology clinics and practices, as well as larger hospital groups and health care systems in the U.S and Australia.